The following consensus is up to date for Dr. Martens as at 25th November 2021

  H1 FY22
6 months ended
30 September 2021
FY22
Year ending
March 2022
FY23
Year ending
March 2023
Revenue £358m £905m £1,052m
EBITDA £88.5m £258m £305m
PBT £61.0m £198m £239m
EPS 4.8p 15.7p 19.0p

 

The above FY22 and FY23 consensus is the mean average of forecasts gathered from 8 out of 8 covering sell-side analysts.

H1 FY22 consensus is the mean average of forecasts gathered from 7 out of 8 covering sell-side analysts.

Legal disclaimer

These financial forecasts are not prepared nor endorsed by Dr. Martens in any way. Dr. Martens has no current or pending duty to verify any individual estimates, and assumes no responsibility to update, revise or otherwise comment on any of the information contained in these forecasts. It should be noted that financial forecasts are, by definition, forward looking, and are therefore subject to various risks and uncertainties which are subject to change at any time.